Patents by Inventor Xiaozhang Zheng

Xiaozhang Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230234953
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 20, 2022
    Publication date: July 27, 2023
    Inventors: Matthew M. WEISS, Xiaozhang Zheng, Xiao Zhu
  • Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11702412
    Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: where R, L, X1, X2, X3, X4, X5, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 18, 2023
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Aleksandra Rudnitskaya, David R. Lancia, Jr.
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230219945
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 17, 2020
    Publication date: July 13, 2023
    Inventors: Nello MAINOLFI, Nan JI, Matthew M. WEISS, Xiaozhang ZHENG, Yi ZHANG, Paul R. FLEMING, Xiao ZHU
  • Crystalline forms of IRAK degraders
    Patent number: 11685750
    Abstract: The present disclosure relates generally to various forms, salts and compositions of compounds useful for the modulation of one or more interleukin-1 receptor-associated kinases (“IRAK”) via ubiquitination and/or degradation and uses of the same in the treatment various diseases.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: June 27, 2023
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Don Corson
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230190940
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 22, 2023
    Inventors: Yi ZHANG, Xiaozhang ZHENG, Xiao ZHU
  • Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
    Patent number: 11649242
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: May 16, 2023
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230132715
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 17, 2020
    Publication date: May 4, 2023
    Inventors: Nan JI, Michael D. SINTCHAK, Yi ZHANG, Xiaozhang ZHENG
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230122219
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 3, 2021
    Publication date: April 20, 2023
    Inventors: Matthew M. WEISS, Xiaozhang ZHENG
  • CDK2 DEGRADERS AND USES THEREOF
    Publication number: 20230110180
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: May 6, 2022
    Publication date: April 13, 2023
    Inventors: Xiaozhang ZHENG, Yi ZHANG, Rober AVERSA, Xiao ZHU, Philip COLLIER
  • PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT)
    Publication number: 20230110003
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Application
    Filed: September 9, 2022
    Publication date: April 13, 2023
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Judith D. Kuntz, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230096599
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 30, 2023
    Inventors: Xiaozhang ZHENG, Xiao ZHU
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230101353
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 30, 2021
    Publication date: March 30, 2023
    Inventors: Nello Mainolfi, Nan Ji, Matthew M. Weiss, Xiaozhang Zheng, Yi Zhang, Paul R. Fleming, Xiao Zhu
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230089916
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.
    Type: Application
    Filed: June 29, 2020
    Publication date: March 23, 2023
    Inventors: Nello MAINOLFI, Nan JI, Matthew M. WEISS, Xiaozhang ZHENG, Yi ZHANG, Paul R. FLEMING
  • PROTEIN DEGRADERS AND USES THEREOF
    Publication number: 20230093080
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.
    Type: Application
    Filed: July 15, 2020
    Publication date: March 23, 2023
    Inventors: Nan JI, Michael D. SINTCHAK, Yi ZHANG, Xiaozhang ZHENG
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230069104
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.
    Type: Application
    Filed: June 29, 2020
    Publication date: March 2, 2023
    Inventors: Nello MAINOLFI, Nan JI, Matthew M. WEISS, Xiaozhang ZHENG, Yi ZHANG, Paul R. FLEMING
  • IRAK degraders and uses thereof
    Patent number: 11591332
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: February 28, 2023
    Assignee: KYMERA THERAPEUTICS, INC.
    Inventors: Matthew M. Weiss, Xiaozhang Zheng, Xiao Zhu
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20230055923
    Abstract: The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).
    Type: Application
    Filed: September 19, 2019
    Publication date: February 23, 2023
    Inventors: Xiaozhang ZHENG, Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, David R. LANCIA, Jr., Jian LIN, Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 11547701
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: January 10, 2023
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • Isoindolines as HDAC inhibitors
    Patent number: 11535607
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 27, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Matthew W. Martin, Pui Yee Ng, Jennifer R. Thomason, Bingsong Han, Aleksandra Rudnitskaya, David R. Lancia, Jr.
  • 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
    Publication number: 20220363651
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 17, 2022
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Heather Davis, Aleksandra Rudnitskaya, David R. Lancia, JR., Kenneth W. Bair, David S. Millan, Matthew W. Martin